AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$MLAB

Kadia Siddhartha purchased $800K of MLAB (indirect holdings)

Kadia Siddhartha (President and CEO) purchased 7,093 indirectly-held shares of MESA LABORATORIES INC /CO/ (MLAB) at $112.80 ($0.80M total) on 2026-08-13.

Original reporting
SEC EDGAR · Kadia Siddhartha
Published Aug 17, 2026, 3:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 4:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MLAB
Neutral
medium confidence
Mentioned
$MLAB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLABNeutralLow
01

Why it matters

A CEO open-market purchase of $800,090.40 is a sentiment signal, but the filing contains no new company performance, guidance, or deal information.

02

Market read

Traders may note the insider buy as a mild positive sentiment datapoint, but it is unlikely to drive a major repricing without additional fundamentals.

03

What to watch

The filing does not state intent, funding source, or whether additional buys are planned; without 10b5-1 context, interpretation is less reliable.

Relevance 6/10Novelty 4/10Timing: filed 2026-08-17, transaction dated 2026-08-13

Background

The article is an SEC Form 4 insider transaction disclosure for Mesa Laboratories (MLAB).

Company-level read

Ticker impact

$MLABNeutralMedium confidence
Context

MLAB disclosed an open-market purchase by President and CEO Kadia Siddhartha for 7,093 shares at $112.80 on 2026-08-13.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction should be muted.

Evidence & confidence

This is a single insider buy with no 10b5-1 plan and no accompanying company guidance, contract, or operational update in the text.

Market effects

Sector

No sector-wide implications are provided; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine, tax-related, or opportunistic and may not reflect a change in business outlook.

Key entities

  • public_company
    MLAB

    Mesa Laboratories Inc /CO/; issuer of the Form 4 insider transaction.

  • insider
    Kadia Siddhartha

    President and CEO who reported an open-market purchase of 7,093 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MLAB insider trading history →

Related articles

$MLABMedAI 8/10

Mesa Laboratories Inc (MLAB) Q2 2027 Earnings Call Highlights: Margin Expansion

Mesa Laboratories (MLAB) reported Q2 2027 earnings, highlighting margin expansion and strategic shifts. CEO Siddhartha Kadia discussed clinical genomics restructuring, aiming for profitability with a focus on pharmacogenomics and oncology. SDC grew 14.6% organically, while BPD saw an 8.2% decline due to timing issues. The company announced a $9.3 million savings plan, with $4.3 million reinvested. Full-year guidance is $250M-$255M revenue and $66M-$68M adjusted EBITDA.

finance.yahoo.com
$MLABMed

Mesa Labs (MLAB) Q2 2027 Earnings Call Transcript

Mesa Labs (MLAB) reported Q2 2027 earnings, highlighting 2.6% organic revenue growth, with Sterilization and Disinfection Control (SDC) up 14.6% and Calibration Solutions up 3.5%. Biopharmaceutical Development saw an 8.2% decline due to timing issues. The company announced cost-cutting measures in Clinical Genomics, reduced net leverage to 1.75x, and provided full-year guidance with revenues expected to grow 5-8%. A $40M share repurchase program was authorized.

finance.yahoo.com
$MLABHigh

Mesa Labs Revenue Rises 2.6%; Issues FY2027 Guidance

Mesa Labs reported Q2 FY2027 revenue of $62.3M, up 2.6% YoY, with net income of $4.3M. Adjusted EBITDA rose 21.1% to $17.3M. The company issued FY2027 guidance, expecting revenue of $250M-$255M and adjusted EBITDA of $66M-$68M. Mesa also announced a $40M share repurchase program.

tradingview.com
$MLABHighAI 8/10

Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance Lakewood, Colorado , November 9, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of critical quality

SEC EDGAR 8-K